Manages pain severe enough to require an opioid analgesic. ANDA 201278, held by Rhodes Pharms. Acetaminophen; Oxycodone Hydrochloride.
As of Nov 16, 2026, ANDA 201278 (Oxycodone And Acetaminophen), held by Rhodes Pharms, was first approved by FDA on Aug 28, 2014, with 12 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Oxycodone and Acetaminophen Tablets, USP are indicated for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. Limitations of Use Because of the risks of addiction, abuse, and misuse, with opioids, even at recommended doses, reserve oxycodone and acetaminophen tablets for use in patients for whom alternative treatment options [e.g., non-opioid analgesics] Have not been tolerated, or are not expected to be tolerated Have not provided adequate analgesia, or are not expected to provide adequate analgesia
| Date | Submission | Status | Documents |
|---|---|---|---|
| Aug 28, 2014 | Original application | Approved |
| Oxycodone And Acetaminophen325MG;5MG · tablet;oral | Acetaminophen; Oxycodone Hydrochloride | Rx |
| Oxycodone And Acetaminophen325MG;7.5MG · tablet;oral | Acetaminophen; Oxycodone Hydrochloride | Rx |
| Oxycodone And Acetaminophen325MG;10MG · tablet;oral | Acetaminophen; Oxycodone Hydrochloride | Rx |
| Jun 18, 2026 | Supplement 23REMS | Approved | None posted |
| Dec 23, 2025 | Supplement 22Labeling · Standard review | Approved | None posted |
| Apr 3, 2024 | Supplement 20Labeling · Standard review | Approved | None posted |
| Dec 15, 2023 | Supplement 19Labeling · Standard review | Approved | None posted |
| Mar 4, 2021 | Supplement 15Labeling · Standard review | Approved | None posted |
| Oct 8, 2019 | Supplement 10Labeling · Standard review | Approved | None posted |
| Oct 23, 2018 | Supplement 9Labeling · Standard review | Approved | None posted |
| Oct 12, 2018 | Supplement 7Manufacturing | Approved | None posted |
| Sep 18, 2018 | Supplement 6REMS | Approved | None posted |
| Feb 10, 2017 | Supplement 5Labeling · Standard review | Approved | None posted |
| Feb 10, 2017 | Supplement 3Labeling · Standard review | Approved | None posted |
| Feb 10, 2017 | Supplement 4Labeling · Standard review | Approved | None posted |
| Aug 28, 2014 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters